Broyhill Asset Management Invests $2.39 Million in Charles River Laboratories International, Inc. (NYSE:CRL)

Broyhill Asset Management bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 12,934 shares of the medical research company's stock, valued at approximately $2,388,000. Charles River Laboratories International comprises approximately 2.1% of Broyhill Asset Management's holdings, making the stock its 18th largest holding.

Other institutional investors and hedge funds have also made changes to their positions in the company. Versant Capital Management Inc grew its stake in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. grew its position in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares during the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new position in Charles River Laboratories International in the 4th quarter valued at $48,000. Tortoise Investment Management LLC raised its position in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after buying an additional 115 shares during the last quarter. Finally, Huntington National Bank lifted its stake in shares of Charles River Laboratories International by 120.6% in the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company's stock worth $55,000 after acquiring an additional 164 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Up 1.6 %

CRL traded up $1.64 during trading hours on Friday, reaching $105.89. 1,658,424 shares of the stock traded hands, compared to its average volume of 891,981. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The company has a market cap of $5.20 billion, a price-to-earnings ratio of 705.91, a PEG ratio of 4.54 and a beta of 1.45. The firm's fifty day simple moving average is $151.07 and its two-hundred day simple moving average is $174.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same period in the previous year, the company earned $2.46 earnings per share. The company's revenue for the quarter was down 1.1% compared to the same quarter last year. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CRL. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their price target for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Robert W. Baird dropped their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. UBS Group restated a "neutral" rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. The Goldman Sachs Group downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. Finally, Barclays cut their price target on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $182.00.

Insider Buying and Selling

In related news, COO Birgit Girshick bought 1,514 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).